vs

Side-by-side financial comparison of MANHATTAN ASSOCIATES INC (MANH) and Ultragenyx Pharmaceutical Inc. (RARE). Click either name above to swap in a different company.

MANHATTAN ASSOCIATES INC is the larger business by last-quarter revenue ($282.2M vs $207.3M, roughly 1.4× Ultragenyx Pharmaceutical Inc.). MANHATTAN ASSOCIATES INC runs the higher net margin — 17.5% vs -62.0%, a 79.5% gap on every dollar of revenue. On growth, Ultragenyx Pharmaceutical Inc. posted the faster year-over-year revenue change (25.9% vs 6.0%). Over the past eight quarters, Ultragenyx Pharmaceutical Inc.'s revenue compounded faster (38.0% CAGR vs 3.1%).

Computer Associates International, Inc., later CA, Inc., and CA Technologies, Inc., was an American multinational enterprise software developer and publisher that existed from 1976 to 2018. CA grew to rank as one of the largest independent software corporations in the world, and at one point was the second largest. The company created systems software that ran in IBM mainframe, distributed computing, virtual machine, and cloud computing environments.

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

MANH vs RARE — Head-to-Head

Bigger by revenue
MANH
MANH
1.4× larger
MANH
$282.2M
$207.3M
RARE
Growing faster (revenue YoY)
RARE
RARE
+19.9% gap
RARE
25.9%
6.0%
MANH
Higher net margin
MANH
MANH
79.5% more per $
MANH
17.5%
-62.0%
RARE
Faster 2-yr revenue CAGR
RARE
RARE
Annualised
RARE
38.0%
3.1%
MANH

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
MANH
MANH
RARE
RARE
Revenue
$282.2M
$207.3M
Net Profit
$49.3M
$-128.6M
Gross Margin
Operating Margin
23.0%
-54.7%
Net Margin
17.5%
-62.0%
Revenue YoY
6.0%
25.9%
Net Profit YoY
-6.3%
3.5%
EPS (diluted)
$0.82
$-1.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MANH
MANH
RARE
RARE
Q1 26
$282.2M
Q4 25
$270.4M
$207.3M
Q3 25
$275.8M
$159.9M
Q2 25
$272.4M
$166.5M
Q1 25
$262.8M
$139.3M
Q4 24
$255.8M
$164.6M
Q3 24
$266.7M
$139.5M
Q2 24
$265.3M
$147.0M
Net Profit
MANH
MANH
RARE
RARE
Q1 26
$49.3M
Q4 25
$52.0M
$-128.6M
Q3 25
$58.6M
$-180.4M
Q2 25
$56.8M
$-115.0M
Q1 25
$52.6M
$-151.1M
Q4 24
$48.0M
$-133.2M
Q3 24
$63.8M
$-133.5M
Q2 24
$52.8M
$-131.6M
Gross Margin
MANH
MANH
RARE
RARE
Q1 26
Q4 25
55.0%
Q3 25
56.6%
Q2 25
57.3%
Q1 25
56.4%
Q4 24
55.8%
Q3 24
55.5%
Q2 24
54.8%
Operating Margin
MANH
MANH
RARE
RARE
Q1 26
23.0%
Q4 25
24.8%
-54.7%
Q3 25
27.5%
-106.9%
Q2 25
27.1%
-64.8%
Q1 25
24.0%
-102.6%
Q4 24
23.7%
-74.3%
Q3 24
28.2%
-94.6%
Q2 24
25.7%
-79.1%
Net Margin
MANH
MANH
RARE
RARE
Q1 26
17.5%
Q4 25
19.2%
-62.0%
Q3 25
21.3%
-112.8%
Q2 25
20.8%
-69.0%
Q1 25
20.0%
-108.5%
Q4 24
18.8%
-80.9%
Q3 24
23.9%
-95.7%
Q2 24
19.9%
-89.5%
EPS (diluted)
MANH
MANH
RARE
RARE
Q1 26
$0.82
Q4 25
$0.86
$-1.28
Q3 25
$0.96
$-1.81
Q2 25
$0.93
$-1.17
Q1 25
$0.85
$-1.57
Q4 24
$0.77
$-1.34
Q3 24
$1.03
$-1.40
Q2 24
$0.85
$-1.52

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MANH
MANH
RARE
RARE
Cash + ST InvestmentsLiquidity on hand
$226.1M
$421.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$205.2M
$-80.0M
Total Assets
$740.5M
$1.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MANH
MANH
RARE
RARE
Q1 26
$226.1M
Q4 25
$328.7M
$421.0M
Q3 25
$263.6M
$202.5M
Q2 25
$230.6M
$176.3M
Q1 25
$205.9M
$127.1M
Q4 24
$266.2M
$174.0M
Q3 24
$215.0M
$150.6M
Q2 24
$202.7M
$480.7M
Stockholders' Equity
MANH
MANH
RARE
RARE
Q1 26
$205.2M
Q4 25
$314.8M
$-80.0M
Q3 25
$309.2M
$9.2M
Q2 25
$278.8M
$151.3M
Q1 25
$245.1M
$144.2M
Q4 24
$299.1M
$255.0M
Q3 24
$278.0M
$346.8M
Q2 24
$240.6M
$432.4M
Total Assets
MANH
MANH
RARE
RARE
Q1 26
$740.5M
Q4 25
$839.4M
$1.5B
Q3 25
$768.8M
$1.2B
Q2 25
$744.7M
$1.3B
Q1 25
$708.2M
$1.3B
Q4 24
$757.6M
$1.5B
Q3 24
$698.1M
$1.5B
Q2 24
$665.3M
$1.6B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MANH
MANH
RARE
RARE
Operating Cash FlowLast quarter
$84.0M
$-99.8M
Free Cash FlowOCF − Capex
$-100.8M
FCF MarginFCF / Revenue
-48.6%
Capex IntensityCapex / Revenue
0.3%
0.5%
Cash ConversionOCF / Net Profit
1.70×
TTM Free Cash FlowTrailing 4 quarters
$-472.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MANH
MANH
RARE
RARE
Q1 26
$84.0M
Q4 25
$147.1M
$-99.8M
Q3 25
$93.1M
$-91.4M
Q2 25
$74.0M
$-108.3M
Q1 25
$75.3M
$-166.5M
Q4 24
$104.7M
$-79.3M
Q3 24
$62.3M
$-67.0M
Q2 24
$73.3M
$-77.0M
Free Cash Flow
MANH
MANH
RARE
RARE
Q1 26
Q4 25
$142.4M
$-100.8M
Q3 25
$87.2M
$-92.7M
Q2 25
$70.1M
$-110.7M
Q1 25
$74.4M
$-167.8M
Q4 24
$101.6M
$-79.5M
Q3 24
$61.3M
$-68.6M
Q2 24
$71.0M
$-79.0M
FCF Margin
MANH
MANH
RARE
RARE
Q1 26
Q4 25
52.7%
-48.6%
Q3 25
31.6%
-58.0%
Q2 25
25.7%
-66.5%
Q1 25
28.3%
-120.5%
Q4 24
39.7%
-48.3%
Q3 24
23.0%
-49.2%
Q2 24
26.8%
-53.7%
Capex Intensity
MANH
MANH
RARE
RARE
Q1 26
0.3%
Q4 25
1.7%
0.5%
Q3 25
2.1%
0.8%
Q2 25
1.5%
1.5%
Q1 25
0.3%
1.0%
Q4 24
1.2%
0.1%
Q3 24
0.4%
1.2%
Q2 24
0.8%
1.4%
Cash Conversion
MANH
MANH
RARE
RARE
Q1 26
1.70×
Q4 25
2.83×
Q3 25
1.59×
Q2 25
1.30×
Q1 25
1.43×
Q4 24
2.18×
Q3 24
0.98×
Q2 24
1.39×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

MANH
MANH

Services$125.7M45%
Cloud subscriptions$117.1M42%
Maintenance$30.6M11%
Hardware$6.5M2%
Software license$2.2M1%

RARE
RARE

Royalty$105.6M51%
Products$101.7M49%

Related Comparisons